BTIG’s recent upgrade of Henry Schein (HSIC), citing solid dental segment trends and cost-saving efforts that support profitability, has drawn fresh attention to the stock and how investors interpret evolving industry pressures.

The recent BTIG upgrade comes after a period where Henry Schein’s 1 month share price return of 11.51% and 1 year total shareholder return of 14.60% suggest improving momentum following more modest multi year gains.

If this shift in sentiment around Henry Schein has you rethinking your watchlist, it could be a good time to broaden your search with the 39 healthcare AI stocks

With Henry Schein trading at US$81.09 and an analyst price target of about US$88, along with an estimated intrinsic value gap, the key question is whether investors are overlooking value or already pricing in future growth.

Most Popular Narrative: 7% Undervalued

Compared with Henry Schein’s last close at $81.09, the most followed narrative points to a fair value of $87.21, framing the recent BTIG upgrade within a broader story about earnings power and future cash flows.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, which is described as supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are described as accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which is expected to support both revenue growth and improved margins.

Want to see how this mix of higher margin segments, recurring software revenues, and assumed efficiency gains is presented as a single valuation story? The narrative leans on specific revenue, margin and earnings trajectories that sit behind that $87.21 fair value, along with a future earnings multiple that differs from today’s. The full breakdown shows exactly which financial levers would need to move, and how far, for Henry Schein to match that implied value.

Result: Fair Value of $87.21 (UNDERVALUED)

However, Henry Schein’s story could shift if competitive pricing continues to pressure distribution margins, or if staffing shortages keep dental patient traffic and procedure volumes subdued.

Another View: Henry Schein Stock Through a Market Multiple Lens

The first valuation framed Henry Schein as undervalued using future cash flows. A simpler cross check looks at pricing relative to earnings. On this measure, Henry Schein trades on a P/E of 23.4x, compared with a peer average of 20.1x and a fair ratio of 24.1x. This points to a stock that is priced richer than peers but close to where the fair ratio suggests the market could settle. For an investor, that mix raises a practical question: is the extra premium a risk to be cautious about, or a price worth paying if the earnings story holds up.

Next Steps

Reading this mix of optimism and concern around Henry Schein, it makes sense to review the numbers yourself and move quickly to shape your own view. You can start with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Henry Schein?

If Henry Schein has sharpened your focus on quality, do not stop here. Use curated stock ideas to spot opportunities that fit your style before others move first.

• Target stability by reviewing companies with resilient finances and conservative risk profiles through the 68 resilient stocks with low risk scores
• Hunt for mispriced quality by scanning the 47 high quality undervalued stocks where solid fundamentals may line up with attractive pricing.
• Spot potential future standouts early by checking the screener containing 20 high quality undiscovered gems before they draw wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.